{"product_id":"terumo-bcg-matrix","title":"Terumo Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eTerumo’s BCG Matrix snapshot highlights which product lines are fueling growth and which are quietly draining capital — a quick reality check for any investor or exec. This preview maps out high-level Stars, Cash Cows, Dogs and Question Marks, but the full report breaks each placement down with data, trend drivers and actionable moves. Buy the complete BCG Matrix to get quadrant-by-quadrant analysis, strategic recommendations, and ready-to-use Word and Excel files that save you weeks of digging.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCell therapy platforms (Terumo BCT)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCell therapy platforms at Terumo BCT sit in a high-growth cell and gene therapy workflow segment—global market ~$7.5B in 2024 with ~25% CAGR—giving real gravity to the business. Strong installed base across 60+ countries, sticky consumables and expanding clinical use sustain momentum. It absorbs investment in software, services and regulatory pathways but returns market leadership if continuously funded.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurovascular (MicroVention) coils \u0026amp; flow tech\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeurovascular (MicroVention) coils \u0026amp; flow tech sit squarely as Stars in Terumo’s BCG matrix: stroke and aneurysm care demand is rising and the portfolio resonates with surgeons through a premium, complex-procedure mix. The global neurovascular devices market was roughly USD 3.6 billion in 2023 and is growing at about a 7% CAGR, supporting continued premium pricing and volume upside. Maintaining leadership requires sustained clinical evidence and robust proctoring\/training programs. Prioritize investigator-led trials, expanded proctor networks, and targeted M\u0026amp;A to broaden the competitive moat.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRadial access portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRadial-first cardiology keeps spreading and Terumo, present in 160+ countries, helped write that playbook; radial adoption exceeded 60% in many key markets by 2024. Guidewires, sheaths and adjuncts move as a system, boosting share and stickiness and driving recurring consumable revenue. Competition is intense, but Terumo’s procedural know‑how and broad portfolio show through. Keep bundling, education and workflow tools humming to protect growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eApheresis systems \u0026amp; software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTherapeutic apheresis and collections are positioned as Stars within Terumo’s BCG matrix, driven by structural shifts in blood centers toward outpatient, personalized therapies and cellular therapy collections. High switching costs, onsite service depth, and validated workflows defend share, while growth requires ongoing software, connectivity, and compliance upgrades to meet regulatory and interoperability demands. Investment to secure multi-year service contracts and scheduled fleet refreshes will lock in long-term revenue and lifetime value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket dynamics: outpatient and cell therapy demand sustain volume growth\u003c\/li\u003e\n\u003cli\u003eDefensive moat: high switching costs and deep service footprint\u003c\/li\u003e\n\u003cli\u003eGrowth drivers: software, connectivity, regulatory compliance upgrades\u003c\/li\u003e\n\u003cli\u003eCapital strategy: invest in contracts and fleet refresh to secure LTV\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePeripheral intervention \u0026amp; embolics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePeripheral intervention \u0026amp; embolics sit in Stars for Terumo as oncology embolization and PAD interventions expand; global peripheral vascular device market reached about $7.2B in 2024 and embolic\/microcatheter demand is growing double digits. Procedure volume growth plus operator specialization favors experienced incumbents; product is capital-light versus large capital devices but requires clinical marketing and KOL-driven evidence. Funding focused R\u0026amp;D and M\u0026amp;A to fill portfolio gaps can outpace category growth.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket_2024: $7.2B peripheral vascular devices\u003c\/li\u003e\n\u003cli\u003eGrowth: double-digit demand for embolics\/microcatheters\u003c\/li\u003e\n\u003cli\u003eModel: capital-light, high clinical marketing need\u003c\/li\u003e\n\u003cli\u003eStrategy: fund evidence, close portfolio gaps, prioritize KOL-led commercialization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCell therapy, neurovascular \u0026amp; radial cardiology drive sticky consumables, software and M\u0026amp;A\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: cell therapy platforms (~$7.5B market 2024, ~25% CAGR), neurovascular (~$3.6B market 2023, ~7% CAGR), peripheral devices (~$7.2B market 2024, double‑digit embolics growth) and radial cardiology (\u0026gt;60% adoption in key markets by 2024) drive recurring consumables, high switching costs and service revenue; sustaining leadership needs continued clinical evidence, software and targeted M\u0026amp;A.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 market\u003c\/th\u003e\n\u003cth\u003eCAGR\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCell therapy\u003c\/td\u003e\n\u003ctd\u003e$7.5B\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003ctd\u003esticky consumables\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeurovascular\u003c\/td\u003e\n\u003ctd\u003e$3.6B (2023)\u003c\/td\u003e\n\u003ctd\u003e~7%\u003c\/td\u003e\n\u003ctd\u003epremium pricing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeripheral\u003c\/td\u003e\n\u003ctd\u003e$7.2B\u003c\/td\u003e\n\u003ctd\u003edouble‑digit\u003c\/td\u003e\n\u003ctd\u003eembolics growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRadial cardiology\u003c\/td\u003e\n\u003ctd\u003eGlobal\u003c\/td\u003e\n\u003ctd\u003en\/a\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60% adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eIn-depth review of each product in Terumo's BCG Matrix, with clear strategy for Stars, Cash Cows, Question Marks and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTerumo BCG one-page dashboard highlighting cash cows and pain points for fast executive decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSyringes \u0026amp; needles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal syringes \u0026amp; needles remain a mature, massive cash cow—the global market is ~USD 10.8B in 2024 with ~6.5% CAGR to 2030, so reliability and scale win. Scale drives margin: large manufacturers report double-digit operating margins on injectable consumables as fixed-costs spread. Keep plants efficient and quality spotless; reinvest excess cash into automation and capacity (robotics\/vision) rather than engaging in price wars. Milk the cash while protecting share through service and supply reliability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiabetes injection consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePen needles (~$3.2B global market in 2024) and insulin syringes (~$1.0B in 2024) are sticky daily-use cash cows for Terumo: modest market growth (~3.5% CAGR), heavy competition, low promo spend but high returns from operations excellence. Priority: hold share, protect pricing, squeeze waste via distribution efficiency and 200–400 bps margin uplift targets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBlood bags \u0026amp; transfusion sets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBlood bags and transfusion sets are hospital staples with long replacement cycles, driving predictable multi‑year contracts for Terumo in 2024. When quality is trusted, procurement renewals stabilize revenue and cash flow. Margins lift through manufacturing yield improvements and logistics finesse, reducing per‑unit cost. Optimize footprint, defend key accounts and bank the cash. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIV catheters \u0026amp; infusion disposables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIV catheters and infusion disposables sit squarely as cash cows for Terumo: commodity-leaning but volume-driven, with global IV catheter market ~USD 3.2 billion in 2024 and forecast CAGR ~5% supporting steady demand; hospital standardization and protocols keep throughput predictable, enabling operational discipline and stable margins.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSKU rationalization: tight SKUs preserves margin\u003c\/li\u003e\n\u003cli\u003eService levels: high uptime and logistics speed\u003c\/li\u003e\n\u003cli\u003eVolume play: scale reduces unit cost\u003c\/li\u003e\n\u003cli\u003eLow growth: focus on efficiency, not aggressive R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardiopulmonary \u0026amp; surgical disposables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePerfusion circuits, grafts, and OR consumables sit in mature, high-volume cardiac and surgical procedures with stable utilization; installed-habit barriers and training drive strong retention and repeat purchases. Incremental 2024 product tweaks sustain pricing power without heavy promotion, enabling reliable margins and predictable cash generation. Run these lines for operational efficiency and steady free cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh procedure volumes sustain demand\u003c\/li\u003e\n\u003cli\u003eTraining and installed base drive \u0026gt;80% repeat use\u003c\/li\u003e\n\u003cli\u003eIncremental innovation preserves pricing\u003c\/li\u003e\n\u003cli\u003eReliable margins support steady cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProtect syringe share, lift margins \u003cstrong\u003e200-400 bps\u003c\/strong\u003e, reinvest in automation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTerumo cash cows: global syringes market ~USD 10.8B (2024) with stable demand; pen needles USD 3.2B and insulin syringes USD 1.0B (2024) offer sticky daily volume; IV catheters USD 3.2B (2024) and blood bags provide predictable hospital cash flow. Priorities: protect share, drive 200–400 bps margin lift via efficiency, reinvest in automation, defend key accounts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 Market (USD)\u003c\/th\u003e\n\u003cth\u003eCAGR\u003c\/th\u003e\n\u003cth\u003eStrategy\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSyringes \u0026amp; needles\u003c\/td\u003e\n\u003ctd\u003e10.8B\u003c\/td\u003e\n\u003ctd\u003e~6.5%\u003c\/td\u003e\n\u003ctd\u003eScale, margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePen\/insulin needles\u003c\/td\u003e\n\u003ctd\u003e3.2B \/ 1.0B\u003c\/td\u003e\n\u003ctd\u003e~3.5%\u003c\/td\u003e\n\u003ctd\u003eProtect share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIV catheters\u003c\/td\u003e\n\u003ctd\u003e3.2B\u003c\/td\u003e\n\u003ctd\u003e~5%\u003c\/td\u003e\n\u003ctd\u003eEfficiency\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBlood bags\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003eStable\u003c\/td\u003e\n\u003ctd\u003eDefend accounts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eTerumo BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the final Terumo BCG Matrix you'll receive after purchase. No watermarks or demo content—just a fully formatted, ready-to-use strategic matrix tailored for Terumo. This exact document will be delivered instantly to your inbox and is editable and print-ready. Use it directly in planning, presentations, or client briefings with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56164060955001,"sku":"terumo-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/terumo-bcg-matrix.png?v=1762725168","url":"https:\/\/portersfiveforce.com\/products\/terumo-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}